Incyte | INCY - Loan Capital


Incyte reported $28.42M in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agenus USD 153.98M 15.68M Mar/2026
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Moderna USD 597M 6M Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.49B 42M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025